China grants licence to Merck’s KEYTRUDA for stomach cancer treatment
By Thomson ReutersJun 25, 2024 | 6:08 AM
BEIJING (Reuters) – China’s National Drug Administration has granted Merck’s KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck is known as MSD outside the United States and Canada.
(Reporting by Beijing newsroom; Editing by David Goodman)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
